Introduction {#sec1}
============

The emergence of antimicrobial resistance (AMR) is a major threat to human health and is occurring at an alarming rate throughout the globe, diminishing the already limited therapeutic options \[[@cit0001]\]. Low-income regions, such as Africa, are at high and particular risk. Such threats are complicated by the underdeveloped regional conditions and socioeconomic factors that are associated with healthcare settings and community-acquired pathogens \[[@cit0002]\]. AMR in Africa is a rising problem and frequently reported from clinical, non-clinical and environmental sources \[[@cit0002], [@cit0003]\].

Carbapenems are potent 46;-lactam antibiotics that are considered as the last resort option for treating serious nosocomial infections caused by a broad spectrum of Gram-negative bacteria \[[@cit0004]\]. Prior to 2000, only few clinical isolates showed resistance to carbapenems, mostly represented by Acinetobacter baumannii and Pseudomonas aeruginosa. Thereafter, carbapenem resistance has emerged as a major, global health concern and a major clinical problem \[[@cit0005]\]. Carbapenemase-producing bacteria has come to the forefront as a global concern representing a serious medical and public health issue due to multidrug resistances (MDRs) that involve valuable therapeutic choices, including the so-called drugs of last resort \[[@cit0006]-[@cit0009]\].

Over the past decade, studies and investigations have reported the problem of AMR in Libya among different nosocomial bacterial, particularly methicillin-resistant *Staphylococcus aureus* (MRSA) \[[@cit0010], [@cit0011]\]. Recent and increasing reports have also documented the carbapenamase-producing bacteria, mainly involving Libyan traveller patients \[[@cit0006], [@cit0012]-[@cit0016]\]. These recent and limited studies have reported different carbapenemase-encoding genes in the Gram-negative bacteria, including the blaVIM-2, blaNDM and OXA-genes \[[@cit0017], [@cit0018]\]. Nevertheless, surveillance and epidemiological investigations on AMR bacterial pathogens in this particular region remain inadequate, limited and incomplete. In this short report, we investigate and provide data on the species spectrum and the antibiotic susceptibility patterns of 94 Gram-negative bacteria that were collected in 2015 from clinical cases at a single Libyan hospital in Tripoli. These strains were isolated and collected on the basis of the expressed resistance to the carbapenem classes. This brief work aimed to report and discuss the current threat and future concern of carbapenemase-producing Gram-negative bacteria in Libyan hospitals.

Methods {#sec2}
=======

The 94 Gram-negative bacterial strains were initially isolated and identified based on cultural and biochemical characteristics (i.e. Gram stain, catalase reactivity, and API 20E system). Isolates were defined and characterized at species level and the antibiotic susceptibility profile was determined using the VITEK automated system (VITEK-Compact 2). The strains were selected and collected based on the expressed resistance to at least one carbapenem class (i.e. meropenem or/and ertapenem) and stored at -20^o^C. The VITEK system tested *A. baumannii* only against meropenem, while the *E. coli* and *K. pneumoniae* were tested against both of the carbapenem classes. The Multidrug resistance phenotypes (MDR) (i.e. based on the expressed resistance to at least 5 different antimicrobial classes) were also characterized.

Results {#sec3}
=======

As a result, 45/94 (48%) were *A. baumannii*, 47/94 (50%) were *K. pneumoniae* and only 2/94 (2%) were *E. coli*. Of the *A. baumannii* strains, 43/45 (96%) showed resistance to meropenem. Of the *K. pneumonia* strains, 33/47 (70%) showed resistance to meropenem and 44/47 (94%) showed resistance to ertapenem ([Table 1](#t0001){ref-type="table"}). Both *E. coli* isolates show resistance to ertapenem and only one strain show resistance to meropenem. A total of 73/94 (78%) of the strains showed different MDR phenotypes; 67% of *A. baumannii* and 91% of *K. pneumoniae* strains.

###### 

Antimicrobial resistance of the collection-strains

  Antimicrobial agents   Proportion of strains (%)   
  ---------------------- --------------------------- -----
  AMP                    100                         100
  AMS                    100                         96
  TZP                    100                         96
  CZ                     100                         100
  FOX                    100                         100
  CAZ                    100                         93
  CRO                    100                         100
  FEP                    70                          96
  ETP                    94                          \--
  MEM                    70                          96
  AMK                    2                           \--
  GEN                    98                          53
  TOB                    98                          27
  CIP                    94                          94
  LEV                    94                          56
  NIT                    98                          100
  SXT                    45                          44

**None; AMP**, Ampicillin; **AMS**, Ampicillin/Sulbactam; **TZP**, Pipracillin Tazobactam; **CZ**, Cefazolin; **FOX**, Cefoxitin; **CAZ**, Ceftazidime; **CRO**, Ceftriaxone; **FEP**, cefepime; **ETP**, Ertapenem; **MEM**, Meropenem; **AMK**, Amikacin; **GEN**, gentamycin; **TOB**, Tobramycin; **CIP**, Ciprofloxacin; **LVX**, levofloxacin; **NIT**, Nitroforantion; **SXT**; Trimethoprim/sulfamethoxazole: co-trimoxazole,

Discussion {#sec4}
==========

*Staphylococcus aureus, Pseudomonas spp.* and *Klebsiella spp*. were previously reported as the most frequent causes of nosocomial infections, highlighting the reported emerging challenge of antimicrobial resistance in Libyan hospitals \[[@cit0010]\]. A recent investigation involving a single Libyan hospital has found *P. aeruginosa*, *A. baumannii* and *S. aureus* as the most identified nosocomial bacterial strains expressing high rates of MDR phenotypes, including to the cephalosporins and carbapenems (personal unpublished 2015 data). In the current brief report, *A. baumannii* and *K. pneumonia* were identified as the dominant bacteria expressing high level of resistance to different carbapenems classes . The *Klebsiella* strains showed a remarkable rate of MDRs and different antimicrobial resistance patterns ([Table 1](#t0001){ref-type="table"}). Previously, the extended spectrum beta-lactamases (ESBLs)- in the Gram-negative isolates from Libya hospitals was reported at a range of 9-15% \[[@cit0010]\].. Generally, MDR and ESBLs are frequent among the clinical strains of Gram-negative rods of *P. aeruginosa*, *A. baumannii and K. pneumonia*, and show the concomitant resistance phenotypes \[[@cit0003], [@cit0013], [@cit0019]\].

The carbapenemase-producing bacteria, are generally recognized as difficult to identify and estimate \[[@cit0009]\]. The current estimates of carbapenemase-producing bacteria for Africa range from 2.3% to 67.7% \[[@cit0008]\]. The North African and Mediterranean regions have recently been designated as an endemic/reservoir area of the carbapenemase-producing bacteria (i.e. OXA-48 type) \[[@cit0009], [@cit0006], [@cit0007], [@cit0014]\]. Globally, KPC, VIM, IMP, NDM, and OXA-48 are the most prevalent β-lactamase classes produced by the carbapenemase-producing bacteria \[[@cit0009]\].

The documented cases of carbapenemase-producing bacteria from Libya have exclusively involved Libyan travellers and described MDR phenotypes in patients with high co-colonization rates and a pre-hospitalization history in Libyan healthcare settings \[[@cit0012]-[@cit0016]\]. These reports have documented MDR in *K. pneumonia* and *A. baumannii* strains harbouring either or a combination of OXA-48, OXA-23 and NDM-1. Other report have also demonstrated the presence of *bla~VIM-2~* gene in *P. aeruginosa* and OXA-carbapenemase-encoding genes (i.e. *bla~OXA-23~*, bla~OXA-24~- and bla~OXA-48~) in *A. baumannii* isolates from hospitalized patients in a Libyan hospital \[[@cit0017]\].

The carbapenemase-producing bacteria, are generally recognized as difficult to identify and estimate \[[@cit0009]\]. The current estimates of carbapenemase-producing bacteria for Africa range from 2.3% to 67.7% \[[@cit0008]\]. The North African and Mediterranean regions have recently been designated as an endemic/reservoir area of the carbapenemase-producing bacteria (i.e. OXA-48 type) \[[@cit0006], [@cit0007], [@cit0009], [@cit0014]\]. Globally KPC VIM IMP NDM and OXA-48 are the most prevalent β-lactamase classes produced by the carbapenemase-producing bacteria \[[@cit0009]\]. The carbapenem-resistant bacteria in the Gram negative bacteria are a global emergent threat and surveillance and monitoring studies are urgently needed in Libya hospitals. Unfortunately, due to limited financial resources, investigating ESBL genes within the current collection was not possible. Urgent actions and investigations are extremely required to evaluate and understand the extent of carbapenemase-Gram-negative bacteria in Libyan health care settings.

Conclusion {#sec5}
==========

The antimicrobial resistance (AMR) pose a serious medical and public health concern. The recent published reports and the current information reveal a current and prospective concern. The reporting and rising of AMR in Libya has been mainly attributed to the consumption of antibiotic drugs (i.e. β-lactam drugs) and to the improved identification methods and laboratory skills. However, epidemiological data and molecular investigations remain inadequate from healthcare settings and absent from the community. Clearly, lack of epidemiological and molecular investigations, inadequate surveillance and monitoring studies, complicated socioeconomic factors and underdeveloped healthcare infrastructures are major factors contributing in the development and spreading of AMR. Professional development of healthcare personnel, educational campaigns to increase awareness of AMR and the need for rational use of antibiotics are also important steps to control the spread of AMR

What is known about this topic {#sec5.1}
------------------------------

-   Carbapenemase-producing bacteria is an emerging global problem especially for the developing regions, particularly for Africa;

-   It is already reported from different regions including from the North African countries.

-   These resistant strains were also reported from Libyan hospitals and travelled patients however limited attention and information are currently available.

What this study adds {#sec5.2}
--------------------

-   This short report reveal the importance to focus on such emergent problem and the associated concern on antimicrobial based therapies particularly for Africa.

-   This short paper provides useful information on the susceptibility patters of clinical isolates and can aid clinicians in providing the suitable therapies;

-   This brief report can also help epidemiologist and clinical bacteriologist to understand the serious concern of carbapenemase-producers and the extent of the problem within the Libya health care system and take appropriate actions.
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